問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Neurology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

更新時間：2023-09-19

張雅婷
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張雅婷

List

44Cases

2022-10-01 - 2026-01-16

Phase III

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

  • Condition/Disease

    Adult patients with candidemia and/or invasive candidiasis

  • Test Drug

    Fosmanogepix CANCIDAS Fosmanogepix Caspofungin Fluconazole

Participate Sites
8Sites

Not yet recruiting8Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

2019-03-01 - 2023-10-07

Phase II

The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients

  • Condition/Disease

    HIV-1 Infection

  • Test Drug

    UB-421

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2019-01-01 - 2023-12-31

Phase III

A phase III, randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-1 infected adults

  • Condition/Disease

    HIV

  • Test Drug

    UB-421

Participate Sites
12Sites

Not yet recruiting10Sites

Recruiting1Sites

2019-04-01 - 2025-12-31

Phase II

Modeling the relationships between functional connectivity and amyloid deposition in Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    F-18 AV-45

Participate Sites
2Sites

Recruiting2Sites

2017-11-01 - 2021-12-08

Phase III

Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

  • Condition/Disease

    Acute primary cerebral hemorrhage

  • Test Drug

    Three-dose combination(telmisartan, amlodipine, indapamide)

Participate Sites
4Sites

Recruiting3Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

2021-11-19 - 2023-05-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-06-14 - 2021-10-19

Phase III

A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed

  • Condition/Disease

    HIV-1 Infections

  • Test Drug

    GSK3515864

Participate Sites
6Sites

Recruiting6Sites

2023-01-01 - 2023-01-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2019-09-11 - 2023-07-06

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

  • Condition/Disease

    HIV-1 and Hepatitis B Co-Infection

  • Test Drug

    Biktarvy

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB